Ardena strengthens executive leadership with appointments of Chief Quality Officer and Chief Information OfficerGhent, Belgium – November 3, 2025 — Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointment of Dipesh Patel as Chief Quality Officer and Peter Rose as Chief Information Officer. These appointments strengthen Ardena’s executive leadership team and reflect its continued focus on quality, compliance, and digital integration across its global network.
Ardena’s New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval for ManufacturingOSS, The Netherlands, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands, and Sweden, announces the full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss. Granted by the Dutch Healthcare Authority, the approval enables GMP manufacturing operations for nanomedicines, marking a major milestone in Ardena’s mission to support clients in bringing innovative therapies to clinic and to market.
Ardena Expands Bioanalytical Services in EuropeGHENT, Belgium, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced a substantial expansion of its Bioanalytical Services in the Netherlands. This strategic investment includes establishing a brand new bioanalytical lab at Ardena’s Pivot Park facility in Oss, along with additional capacity and new GLP capabilities to its Bioanalytical Center of Excellence in Assen, aimed at meeting rising client demand for comprehensive, cutting-edge bioanalytical services.
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from CatalentGhent, Belgium, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced it has signed a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey. This acquisition will significantly enhance Ardena’s capabilities in downstream late-stage and small-scale commercial manufacturing of oral drug products, supporting its strategy to become a leading global CDMO offering integrated solutions across the entire pharmaceutical development lifecycle.
